5:18 PM
 | 
Jul 18, 2013
 |  BC Extra  |  Clinical News

Novartis' dovitinib misses in Phase III RCC trial

Novartis AG (NYSE:NVS; SIX:NOVN) disclosed in its 2Q13 earnings that dovitinib lactate ( TKI258) missed the primary endpoint of improving progression-free survival (PFS) vs. Nexavar sorafenib from Bayer AG (Xetra:BAYN) and Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) in a Phase...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >